Latest Market Entry News

Smart Parking Limited has reported robust H1 FY25 results, underpinned by a strategic acquisition of Peak Parking LP and a fully underwritten $45 million equity raise to fund its US expansion.

Smart Parking Limited is set to expand its global footprint by acquiring US-based Peak Parking LP for up to USD 36 million, backed by a fully underwritten equity raise and expanded debt facility. The deal promises significant EPS accretion and strategic growth opportunities in the lucrative US parking market.

Ovanti Limited has secured board approval for its ambitious US market entry plan targeting $500 million in total transaction volumes within two years, focusing on underserved consumers in the Southern States.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Micro-X Ltd has announced a $6 million capital raising alongside a $2.4 million strategic investment from Billion Prima, underpinning its pivot towards medical imaging and cashflow stability.

Enova Mining reports multiple drill intercepts exceeding 15% titanium dioxide at its CODA North project, highlighting significant co-mineralisation with rare earth elements and reinforcing the project's multi-commodity potential.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Environmental Clean Technologies Limited has formed a joint venture and launched field trials for its innovative COLDry lignite-nitrogen fertiliser, marking a pivotal step toward commercialisation and revenue generation.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.